Shujing Xu obtained her PhD degree in medicinal chemistry from Shandong University in 2024. She is currently a postdoctoral in Shandong University. Her research interests involve the discovery of novel antiviral agents (HIV, HBV, CHIKV, DENV) based on rational drug design and phenotypic screening. She has led four research projects, including the National Science Foundation of China project, the China Postdoctoral Science Foundation, the Postdoctoral Fellowship Program of CPSF, and the Postdoctoral Innovation Program of Shandong Province. To date, she has published over 50 papers in international peer-reviewed journals, such as The Innovation, J Med Chem, and Acta Pharm Sin B, with an H-index of 15, while she has participated in the compilation of 4 monographs and filed 7 patents. Additionally, she has participated in over ten domestic and international academic conferences and was invited to give reports at the 37th International Conference on Antiviral Research, the 2023 National Graduate Student Pharmacy Academic Forum, and the 2024 China Pharmaceutical Conference. Won the Travel Award of 37th International Conference on Antiviral Research (2024.5, Gold Coast, Australia), the First Prize at the 2023 National Graduate Student Pharmacy Academic Forum(2023.11, Shenzhen, China) as well as multiple outstanding poster awards.